Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02583919

Public ClinicalTrials.gov record NCT02583919. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of ISIS-GCGRRx in combination with metformin versus placebo

Study identification

NCT ID: NCT02583919
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Enrollment: 79 participants

Conditions and interventions

Conditions

Type 2 Diabetes

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2015 (Actual)
Primary completion: Dec 15, 2016 (Actual)
Completion: May 11, 2017 (Actual)
Last update posted: Jun 25, 2018

2015 – 2017

United States locations

U.S. sites: 19
U.S. states: 11
U.S. cities: 17

Facility	City	State	ZIP	Site status
Ionis Investigational Site	Greenbrae	California	94904	—
Ionis Investigational Site	Huntington Park	California	90255	—
Ionis Investigational Site	La Mesa	California	91942	—
Ionis Investigational Site	Los Angeles	California	90057	—
Isis Investigational Site	Spring Valley	California	91978	—
Ionis Investigational Site	Port Orange	Florida	32127	—
Ionis Investigational Site	Marietta	Georgia	30060	—
Ionis Investigational Site	Oxon Hill	Maryland	20745	—
Ionis Investigational Site	New York	New York	10016	—
Ionis Investigational Site	Greensboro	North Carolina	27410	—
Ionis Investigational Site	Morehead City	North Carolina	28557	—
Ionis Investigational Site	Cincinnati	Ohio	45219	—
Ionis Investigational Site	Cincinnati	Ohio	45245	—
Ionis Investigational Site	Eugene	Oregon	97404	—
Ionis Investigational Site	Spartanburg	South Carolina	29303	—
Ionis Investigational Site	Houston	Texas	77036	—
Ionis Investigational Site	Houston	Texas	77074	—
Ionis Investigational Site	Katy	Texas	77450	—
Ionis Investigational Site	Olympia	Washington	98502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02583919, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 25, 2018 · Synced Oct 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02583919 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →